Comparison of the Modified Low-Dose Cytarabine with 5-Day Decitabine Therapy for Elderly AML Patients Unfit for Intensive Chemotherapy

Classical low-dose cytarabine (LDAC; ≤ 20 mg SQ BID for 10 days) remains a standard option for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, although long-term results were unsatisfactory. Recently, hypomethylating agents, such as decitabine and azacitidine, have been proved to have better outcomes than the classical LDAC.